Serine Proteinase Inhibitors
"Serine Proteinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
Descriptor ID |
D015842
|
MeSH Number(s) |
D27.505.519.389.745.800
|
Concept/Terms |
Serine Proteinase Inhibitors- Serine Proteinase Inhibitors
- Serine Proteinase Antagonists
- Serine Endopeptidase Inhibitors
- Serine Protease Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Serine Proteinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Serine Proteinase Inhibitors".
This graph shows the total number of publications written about "Serine Proteinase Inhibitors" by people in this website by year, and whether "Serine Proteinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2018 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serine Proteinase Inhibitors" by people in Profiles.
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
-
Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovasc J Afr. 2019 Sep/Oct 23; 30(5):279-284.
-
Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 10; 277:483-492.
-
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
-
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
-
PIVL, a new serine protease inhibitor from Macrovipera lebetina transmediterranea venom, impairs motility of human glioblastoma cells. Matrix Biol. 2013 Jan; 32(1):52-62.